Predictors of Enduring PTSD After an Industrial Disaster
To the Editor: Only a few studies have examined the long-term effects (more than one year) of mass trauma on victimized communities (1, 2) . On September 21, 2001 , a petrochemical plant exploded in the city of Tou louse, France. Victims were sUlveyed by using self-report questionnaires that assessed peri traumatic distress and dissociation and acute stress. A hierarchical multiple regression con ducted with survey data gathered six months after the explOSion indicated that all three constructs explained unique variance, accounting for 62% of the variance in symptoms of post traumatic stress disorder (ITSD ) (3). Here we report the results of a fol low-up survey conducted 15 months after the explosion. The survey used the same predictors plus a measure of depreSSion.
Five to ten weeks after the explo sion, 892 potential study participants were sent self-report questionnaires to assess symptoms of acute stress (Stanford Acute Stress Reaction Questionnaire) and depreSSion (Beck Depression Inventory). The 391 per sons who responded were sent anoth er self-report questionnaire six months after the explOSion. The sec ond survey retrospectively assessed peritraumatic dissociation (Peritrau matic Dissociative Experiences Ques tionnaire) and distress (Peritraumatic Distress Inventory) as well as current PTSD symptoms (Posttraumatic Stress Disorder Checklist). Fifteen months after the explOSion, the 200 participants who responded to the second survey were sent the same questionnaire assessing ITSD symp toms, and 129 persons responded to this third survey.
To analyze the relationship be tween predictors and PTSD symp toms at 15 months, we computed Pearson correlations. Strong correla tions with PTSD symptoms were found for peritraumatic dissociation (r=.50, p<.Ol), peritraumatic distress (r=.58, p<.OI), acute stress symptoms (r=.71, p<.OI ), and depression symp toms (r=.61 , p <.O I). We computed a hierarchical multiple linear regres sion with ITSD symptom score as the dependent variable. Peritraumat ic dissociation was entered first, fol lowed by peri traumatic distress in the second step, symptoms of acute stress in the third step, and symp toms of depression in the fourth step. The model accounted for 59% of the variance in PTSD symptoms. All of our predictors were strongly correlat ed with persistent PTSD symptoms 15 months after exposure.
The num ber of dropouts and retro spective ratings of the peritrawnatic responses should be acknowledged as potentially limiting the generalizabili ty of these results. However, the study fo und that peritraumatic dissociation and distress, acute stress, and depres sion were related to the development and persistence of PTSD symptoms after an industrial disaster. Loss of control and helplessness-anger, meas ured with the Peritraumatic Distress Inventory, were strong predictors of posttrawnatic stress one year after the World Trade Center disaster (4 
LETTERS
We first looked at antidepressant prescriptions . Of the 776 Scandina vian men in the sample, 259 (32%) (age-adjusted 95% confidence inter val [CI)=2S.5-35.2) filled a prescrip tion for antidepressants in the ISO days before death. The correspon ding figures were 176 of the 333 Scandinavian women in the sample (52%) (CI=46.7-57.5), 32 of the 102 foreign-born men (3 1%) (CI=21.6-39.5), and 21 of the 44 foreign-born women (43%) (CI=2S.7-58.1).
We also examined use of antipsy chotic drugs. Among Scandinavian men, 100 (13%) (CI=1O.1-14.5) filled a prescription for an antipsychotic in the ISO days before death. The corre sponding figures were 81 of the Scan dinavian women (24%) (CI=19.5 28.9), 19 of the foreign-born men (18%) (10.7-25.4), and 16 of the for eign-born women (32%) (CI=19.8-44.6). Use of lithium was 2% or less in all groups.
As a comparison we analyzed use of these drugs among persons aged 18 to 84 years in the Swedish population in 2006 by country of birth. Among Scandinavian men, 6.1% (CI=6.05 6.10) had at least one filled prescrip tion for an antidepressant. The corre sponding figure for foreign-born men was 6.5% (CI =6.43-6.59). Among Scandinavian women the figure was 11.7% (CI=11.68--11.76), compared with ILl % (C I= 1 1.02-1 1.20) for for eign-bom women. We did not analyze differences in inpatient or outpatient admission before suicide, although we have previously commented on postdischarge suicides in Sweden (2) .
We have some minor concerns about the study by Ray and colleagues (1) . Data used in that study repre sented suicides in different periods 1986 to 2004. Over those years, at least in Sweden, policies in regard to inpatient care changed. We also sus pect that use of antidepressants in creased substantially in the United States since the early 1990s as a result of the introduction of selective sero tonin reuptake inllibitors (SSRIs). The increase in use of SSRIs in Swe den was sixfold between 1990 and 2004. In the study by Ray and col leagues, the mean age of African Americans who committed suicide was also nearly ten years lower than that of whites, which may indicate so cioeconomic or other differences in the underlying white and African American populations from which the samples were drawn.
Although one might suspect rela tive undertreatment of psychiatric disorders in the non-Scandinavian population in Sweden, it could not be verified by our analyses because we studied only drug utilization without Imowledge of the underlying disease prevalence . However, the rates of prescription were similar for Scandi navians and foreign-born persons in our sample who filled a prescription for an antidepressant in the months before they committed suicide-and who therefore could be said to have been suffering from a severe mood disorde r. This, together with the ob served similar rates of prescription in the general population, could indi cate equal access to drug treatment. The study by Ray and colleagues highlights an important issue in re search on socioeconomic inequalities in care. Racial-ethnic differences in the use of medications may result from differences in religiOUS and cul tural beliefs that can affect both health-seeldng behavior and attitudes toward suicide.
Rickard This is not data from a limited study; it instead concerns information on a national level for ALL suicides (18-84 years) for 2006. The information is unique; registries now exist in Sweden making it possible for the National Board of Health and Welfare to see how many of the suicides were preceded by psychiatric drug treatment.
Among a total number of 377 women who committed suicide, 197 (52%) had filled a prescription for antidepressants within 180 days before their death . And 29 women (8%) ha filled a prescription for neuroleptics ("anti psychotics") ONLY within 180 days before the suicide.
This means that 229 women -60% -of those who committed suicide (18-84) in Sweden (2006) had filled a prescription for antidepressant drugs OR neuroleptics within 180 days before their suicide.
Neuroleptics were involved in total in 97 (26%) of the suicides among women , (68 women, 18%, got BOTH antidepressants and neuroleptics). NOT included in these figures is the percentage of women who got other forms of psychiatric drugs, like benzodiazepines.
The data are revealed just after the news broke that pharmaceutical companies have systematically hidden negative and exaggerated positive results in their clinical trials of antidepressants (see article Antidepressant Studies Unpublished in NYT), thus misleading patients and doctors for many years.
In general, pharmaceutical companies have used a "blackmail strategy" to get doctors and sad patients to believe that they MUST use the drugs -or else. In ads with pictures of gravestones they have proclaimed: "A depression can end unexpectedly fast" (Wyeth for Effexor.) Leading psychiatrists with financial interests in increased sales have been writing endlessly in medical journals about the "protective effect" of antidepressants against suicide. Shamelessly false statements that the psychiatric drugs correct a chemical imbalance (like a lack of serotonin) in the brain are still part of the official drug labels: "In depression the normal access to these [chemical] Senior officials at the Board were not interested in revealing anything more about this. They had adopted the marketing lines of pharmaceutical companies and relied on evaluations from well-known Swedish SSRI-proponents, (like psychiatrists G. Isacsson and A.L. von Knorring) who for more than a decade have touted the new antidepressants as "life saving". A senior official even said that "evidence based treatment of the underlying psychiatric disorder can reduce the risk for suicide", referring to the "protective effect" that he believed antidepressant drugs had. The data about the large percentage of persons who had committed suicide, after having been "treated" with psychiatric drugs, were brushed aside by the official, saying the data "cannot currently be seen as a representative source for a discussion about these questions" (!) Neuroleptics were involved in total in 119 (14%) of the suicides among men, (78 men, 9%, got BOTH antidepressants and neuroleptics). NOT included in these figures is the percentage of men who got other forms of psychiatric drugs.
Thus it can be said that 561 (45%) of ALL 1255 persons (18-84) who committed suicide in Sweden 2006 had filled a prescription for antidepressant drugs OR neuroleptics (not at all counting other psychiatric drugs) within 180 days before their suicide.
A certain number of the persons killing themselves can be expected to be suffering from drug induced akathisia -an extreme inner restlessness, a feeling of having to creep out of ones skin , a completely unbearable condition. It is CAUSED by the psychiatric drugs, not by any "underlying disease". Akathisia is a condition that can make a person commit violent acts against self or others. It is a condition officially recognized and taken up in the warning texts for the drugs. A number of the persons can also be expected to be affected by mania or hypomania -again CAUSED by the drugs; conditions also officially recognized; conditions that can lead to suicide.
Some of the valid questions in an objective investigation of suicides, where psychiatric drugs preceded the tragic event, would be: Was the suicide an effect of an unbearable condition created by the drugs (like akathisia)? Had the drug dose been increased -with a catastrophic result -when the worsened condition in actual fact was caused by the drug (while being blamed on the "underlying disease")? Had the patient been subject to an abrupt discontinuation (with severe withdrawal symptoms as the result)? Was the catastrophic result very likely caused by concomitant use of psychiatric drugs? Had the patient been informed about all the serious harmful effects that these drugs can cause?
None of these questions are part of the form used when investigation suicides, worked out by senior officials at the National Board of Health and Welfare. These questions would -if asked and the answers used -save lives. But they would also threaten the profits of pharmaceutical companies and the careers of their hired psychiatrists. Therefore they cannot be asked.
The Swedish government has been notified about the concealment of data at the National Board of Health and Welfare (the hiding of data and neglect of analysis of drug induced harmful effects is decided at the very top; despite lower officials at the Board wanting to do a good job and let the public know the real story). The Minister for Elderly Care and Public Health (Maria Larsson) has not at all acted to make the hidden data known to the public. The Minister for Health and Social Affairs (Goran Hagglund) has been asked in parliament, the Riksdag, to start a formal investigation inte the violence inducing effect (against self and others) of different psychiatric drugs, but his answer shows -at best -that he is living far from the real world . This is his view about the effectiveness of medical agencies, the adverse event reporting system and the speed of actions taken to protect the public: "If new data somewhere in the world indicate that a medical drug in use can have up to now unknown harmful effects, an alarm goes out that reaches responsible authorities over the world . The Medical Products Agency [the Swedish medical agencYJ fast conveys the information to prescribers and to pharmacies in Sweden." (Answer in Swedish parliament, the Riksdag , December 2007.)
Well, now "an alarm" goes out, that data buried in the registries at the National Board of Health and Welfare -very close to the Minister -show that psychiatric drugs are behind an incredible amount of suicides. Will doctors and patients be told about it? And what consequences will it have for the "treatment guidelines"?
(Very much is NOT KNOWN about the psychiatric treatment preceding the suicides above.
For example the use of other psychiatric drugs or ECT in these cases are still completely concealed. The National Board of Health and Welfare has not published any documents about this. Some persons might want to verify some of the figures above. They can actually do so in a newly published English article. The astonishing data above are made part of a published letter about "ethnic differences in antidepressant treatment". This subject is of course of relative disinterest -especially as no differences were found -compared to the facts revealed that 52% of all women who committed suicide had gotten antidepressant drugs and 26% had gotten neuroleptics. 
